Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 4, 2020

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2026

Conditions
Hematologic DiseasesAcute Leukemia in RemissionChronic Myelogenous Leukemia - Chronic PhaseChronic Myelogenous Leukemia, Accelerated PhaseChronic Myelogenous Leukemia, Blastic PhaseMyelodysplastic SyndromesMantle Cell LymphomaFollicular LymphomaDiffuse Large B Cell LymphomaNon Hodgkin LymphomaGraft Vs Host DiseaseGraft-versus-host-disease
Interventions
DRUG

Vorinostat

"* HLA-matched BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 10 days prior to transplant (day -10), until day +30 post-transplant.~* Haploidentical BMT recipients: Vorinostat 30, 45 or 60 mg/m2 BID (100 mg/m2 BID maximum) PO from 5 days after transplant (day +5), until day +30 post-transplant"

PROCEDURE

Blood and Marrow Transplant (BMT)

Undergo allogeneic BMT according to local site institutional practice.

DRUG

Tacrolimus (or cyclosporine)

Tacrolimus (or cyclosporine if tacrolimus becomes in shortage during the study period) will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.

DRUG

Methotrexate

HLA-matched BMT recipients: Methotrexate will be used in combination with tacrolimus (or cyclosporine) for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.

DRUG

Mycophenolate Mofetil (MMF)

Haploidentical BMT recipients: MMF will be used in combination with post-transplant cyclophosphamide and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. MMF will start on day +5 and discontinue after the last dose on day +35 or may be continued if active GVHD is present. Given intravenously (preferred) or orally at a dose of 15 mg/kg/dose three times a day (based upon adjusted body weight) with the maximum total daily dose not to exceed 3 grams.

DRUG

Cyclophosphamide

Haploidentical BMT recipients: Post-transplant cyclophosphamide (PT-Cy) will be used in combination with MMF and tacrolimus (or cyclosporine) for standard GVHD prophylaxis. PT-Cy (50 mg/kg/dose) given for two days, Days +3 and +4 after transplantation.

Trial Locations (7)

30322

Emory University, Atlanta

37232

Vanderbilt-Ingram Cancer Center, Nashville

46202

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

48109

University of Michigan Health System, Ann Arbor

48202

Henry Ford Hospital, Detroit

53226

Medical College of Wisconsin, Milwaukee

80045

University of Colorado, Aurora

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER